Lanadelumab, which became available for poorly controlled HAE in Australia immediately prior to the study period (December 2021), showed a rapid adoption, largely in subjects on C1 Inhibitor concentrates (C1-INH) or with poor disease control, aligning with expectations. This evidence concerns the gene SERPING1 and hereditary angioedema.